BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,497,948 | -18.9% | 22,006 | -2.7% | 0.02% | -14.3% |
| Q2 2023 | $1,846,471 | +10.9% | 22,620 | +0.8% | 0.02% | +5.0% |
| Q1 2023 | $1,664,749 | -10.3% | 22,439 | +0.2% | 0.02% | -13.0% |
| Q4 2022 | $1,856,429 | +20.5% | 22,399 | +312.8% | 0.02% | +9.5% |
| Q3 2022 | $1,541,000 | -16.8% | 5,426 | +1.5% | 0.02% | -12.5% |
| Q2 2022 | $1,853,000 | -18.3% | 5,345 | +2.0% | 0.02% | 0.0% |
| Q1 2022 | $2,268,000 | -15.4% | 5,238 | +1.1% | 0.02% | -11.1% |
| Q4 2021 | $2,681,000 | +8.6% | 5,183 | +1.7% | 0.03% | +12.5% |
| Q3 2021 | $2,469,000 | -84.0% | 5,096 | -85.1% | 0.02% | -84.2% |
| Q2 2021 | $15,430,000 | +15.8% | 34,269 | -1.8% | 0.15% | +8.6% |
| Q1 2021 | $13,327,000 | +16.8% | 34,895 | -2.9% | 0.14% | +8.5% |
| Q4 2020 | $11,409,000 | +28.0% | 35,927 | -0.1% | 0.13% | +8.4% |
| Q3 2020 | $8,910,000 | -5.4% | 35,967 | +0.9% | 0.12% | -10.5% |
| Q2 2020 | $9,415,000 | +40.0% | 35,653 | +0.6% | 0.13% | +17.7% |
| Q1 2020 | $6,723,000 | -10.7% | 35,456 | +3.4% | 0.11% | +17.7% |
| Q4 2019 | $7,527,000 | +13.3% | 34,288 | +1.0% | 0.10% | +4.3% |
| Q3 2019 | $6,643,000 | -5.6% | 33,951 | +0.6% | 0.09% | -7.1% |
| Q2 2019 | $7,036,000 | +6.6% | 33,750 | +1.5% | 0.10% | +3.1% |
| Q1 2019 | $6,602,000 | +36.2% | 33,251 | -0.7% | 0.10% | +20.0% |
| Q4 2018 | $4,846,000 | -25.9% | 33,482 | +4.5% | 0.08% | -14.0% |
| Q3 2018 | $6,538,000 | +37.2% | 32,030 | -0.6% | 0.09% | +31.0% |
| Q2 2018 | $4,767,000 | +2.3% | 32,217 | +4.4% | 0.07% | -1.4% |
| Q1 2018 | $4,660,000 | +18.4% | 30,852 | +1.5% | 0.07% | +20.0% |
| Q4 2017 | $3,937,000 | +7.0% | 30,390 | -0.1% | 0.06% | 0.0% |
| Q3 2017 | $3,678,000 | +3.8% | 30,428 | +0.8% | 0.06% | -1.6% |
| Q2 2017 | $3,545,000 | +19.8% | 30,174 | +3.7% | 0.06% | +17.3% |
| Q1 2017 | $2,959,000 | +0.5% | 29,111 | +1.7% | 0.05% | -5.5% |
| Q4 2016 | $2,945,000 | -4.6% | 28,637 | +1.5% | 0.06% | -11.3% |
| Q3 2016 | $3,088,000 | -0.9% | 28,205 | +2.1% | 0.06% | -6.1% |
| Q2 2016 | $3,116,000 | +27.8% | 27,629 | +7.1% | 0.07% | +22.2% |
| Q1 2016 | $2,439,000 | +6.0% | 25,801 | +1.0% | 0.05% | +3.8% |
| Q4 2015 | $2,300,000 | +1.2% | 25,553 | +3.9% | 0.05% | -3.7% |
| Q3 2015 | $2,273,000 | -3.5% | 24,587 | +2.8% | 0.05% | +3.8% |
| Q2 2015 | $2,356,000 | -3.8% | 23,922 | -2.0% | 0.05% | -1.9% |
| Q1 2015 | $2,449,000 | +13.4% | 24,417 | +4.5% | 0.05% | +8.2% |
| Q4 2014 | $2,160,000 | – | 23,376 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |